Information Provided By: 
Fly News Breaks for October 6, 2015
OREX
Oct 6, 2015 | 06:51 EDT
Piper Jaffray analyst Charles Duncan cut his price target for Orexigen shares to $11 saying traction for Contrave, while good, is slightly below his expectations. He continues to view Contrave as a "novel asset" with large market potential of $700M in annual revenue, however. Duncan views the company's current market capitalization of $270M as a "market inefficiency" relative to the potential of the Contrave franchise. Duncan reiterates an Overweight rating on Orexigen.
News For OREX From the Last 2 Days
There are no results for your query OREX
